目的观察丝裂原激活蛋白激酶(mitogen activated protein kinases,MAPK)抑制剂对弓形虫速殖子侵入细胞的影响。方法 IFA 荧光标记检测在不同剂量抑制剂作用下及在不同时间其宿主细胞感染速殖子的差异;SDS-PAGE 和 Western blot 分析 MA...目的观察丝裂原激活蛋白激酶(mitogen activated protein kinases,MAPK)抑制剂对弓形虫速殖子侵入细胞的影响。方法 IFA 荧光标记检测在不同剂量抑制剂作用下及在不同时间其宿主细胞感染速殖子的差异;SDS-PAGE 和 Western blot 分析 MAPK 的表达及其相对活性。结果在 PD980591μM 和10μM 作用下其感染率仅分别为对照组的18.00%(u=9.03,P<0.01)和14.80%(u=7.93,P<0.001);在 PD98059 50μM 作用下宿主细胞感染率在24h 和48h 分别为对照组的55.45%(u=3.58,P<0.01)和49.15%(u=4.08,P<0.01);与对照比较,其 MAPK 的相对活性明显下降,10μM 和50μM 组分别降低了43.03%(u=2.72,P<0.01)和78.79%(u=5.74,P<0.001)。结论 PD98059通过作用于 MAPK 信号转导途径而抑制速殖子侵入宿主细胞的过程。展开更多
The usefulness of serum C-reactive protein, an inflammatory marker, to predict mortality risk in patients who have ischemic cardiomyopathy was investigated. C-reactive protein was measured in 123 men who underwent car...The usefulness of serum C-reactive protein, an inflammatory marker, to predict mortality risk in patients who have ischemic cardiomyopathy was investigated. C-reactive protein was measured in 123 men who underwent cardiac catheterization and were noted to have left ventricular ejection fraction ≤45%and significant angiographic coronary artery disease. They were prospectively followed for 3 years. Higher levels of C-reactive protein were associated with increased mortality rate. This correlation was independent of other prognostic factors, such as age, ejection fraction, symptoms of severe congestive heart failure, use of angiotensin-converting enzyme inhibitors, and use of βblockers.展开更多
文摘The usefulness of serum C-reactive protein, an inflammatory marker, to predict mortality risk in patients who have ischemic cardiomyopathy was investigated. C-reactive protein was measured in 123 men who underwent cardiac catheterization and were noted to have left ventricular ejection fraction ≤45%and significant angiographic coronary artery disease. They were prospectively followed for 3 years. Higher levels of C-reactive protein were associated with increased mortality rate. This correlation was independent of other prognostic factors, such as age, ejection fraction, symptoms of severe congestive heart failure, use of angiotensin-converting enzyme inhibitors, and use of βblockers.
